GTHP — Guided Therapeutics Cashflow Statement
0.000.00%
- $33.43m
- $35.69m
- $0.01m
Annual cashflow statement for Guided Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.279 | -2.07 | -4.34 | -3.49 | -2.42 |
| Depreciation | |||||
| Non-Cash Items | -0.813 | 0.4 | 2.31 | 1.84 | 0.286 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.783 | 0.078 | 0.549 | -0.105 | 1 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -1.88 | -1.59 | -1.48 | -1.75 | -1.12 |
| Capital Expenditures | -0.001 | -0.014 | -0.031 | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | — | 0 | — |
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -0.001 | -0.014 | -0.031 | 0 | — |
| Financing Cash Flow Items | — | 0.312 | 0 | — | 0.806 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1.16 | 2.07 | 3.18 | 0.024 | 0.916 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.717 | 0.461 | 1.67 | -1.72 | -0.203 |